Ankara University, Faculty of Medicine, Department of Cardiology - Ankara, Turkey.
University of Health Sciences, Etlik City Hospital, Department of Cardiology - Ankara, Turkey.
Rev Assoc Med Bras (1992). 2024 Aug 16;70(7):e20240423. doi: 10.1590/1806-9282.20240423. eCollection 2024.
Nowadays, the frequency of complications is also increasing following the increasing frequency of coronary angiography and percutaneous coronary intervention. Contrast-induced nephropathy is one of the most common of these complications. This study aimed to investigate the relationship between the Osaka prognostic score, which has previously been shown to have prognostic importance in gastrointestinal malignancies, and the development of contrast-induced nephropathy.
The study retrospectively examined the data of 1,498 patients who underwent coronary angiography and percutaneous coronary intervention due to acute coronary syndrome between 2018 and 2023. Demographic characteristics and laboratory findings were retrospectively collected from patients' charts and electronic medical records.
Osaka prognostic score (0.84±0.25 vs. 2.2±0.32, p<0.001) was higher in patients who developed contrast-induced nephropathy. Also, Osaka prognostic score [OR 2.161 95%CI (1.101-4.241), p<0.001] was found to be an independent risk factor along with age, diabetes mellitus, systolic pulmonary artery pressure, hemoglobin, hemoglobin, C-reactive protein, albumin, N-terminal brain natriuretic peptide, and systemic immune-inflammation index. The receiver operating characteristic curve showed that the optimal cutoff value of Osaka prognostic score to predict the development of contrast-induced nephropathy was 1.5, with a sensitivity of 83.4 and a specificity of 65.9% [area under the curve: 0.874 (95%CI: 0.850-0.897, p≤0.001)].
Osaka prognostic score may be an easily calculable, user-friendly, and useful parameter to predict the development of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention after acute coronary syndromes.
如今，随着冠状动脉造影和经皮冠状动脉介入治疗的频率增加，并发症的频率也在增加。对比剂肾病是最常见的并发症之一。本研究旨在探讨先前在胃肠道恶性肿瘤中具有预后意义的大阪预后评分与对比剂肾病发展之间的关系。
该研究回顾性分析了 2018 年至 2023 年间因急性冠状动脉综合征而行冠状动脉造影和经皮冠状动脉介入治疗的 1498 例患者的数据。从患者病历和电子病历中回顾性收集人口统计学特征和实验室检查结果。
发生对比剂肾病的患者的大阪预后评分（0.84±0.25 与 2.2±0.32，p<0.001）较高。此外，大阪预后评分[OR 2.161 95%CI（1.101-4.241），p<0.001]与年龄、糖尿病、收缩压肺动脉压、血红蛋白、C 反应蛋白、白蛋白、N 末端脑钠肽和全身免疫炎症指数一起被发现是独立的危险因素。受试者工作特征曲线显示，大阪预后评分预测对比剂肾病发展的最佳截断值为 1.5，其敏感性为 83.4%，特异性为 65.9%[曲线下面积：0.874（95%CI：0.850-0.897，p≤0.001)]。
大阪预后评分可能是一种易于计算、易于使用且有用的参数，可预测急性冠状动脉综合征后行经皮冠状动脉介入治疗的患者发生对比剂肾病的情况。
